UK

Outcomes Based Healthcare and My Diabetes My Way have been selected as Health Data Research UK (HDRUK) Sandbox projects.

The Clinical Coding and Schedule Development (CCSD) group develops and maintains procedural and diagnostics nomenclature for private payers in England. New procedure codes concern scar revision, robotic-assisted thymectomy, prophylactic oophorectomy/ hysterectomy, percutaneous electrical nerve stimulation, delivery of fraction of proton beam therapy for non-ocular adult tumors and diagnostic codes for myriad breast and ovarian cancer panel 101 test, clinical exome sequencing MPLA test, and others. The codes are introduced with a recommended adoption date being the 1st of February 2020. The documents also contain a list of textual changes in codes and inactivated codes.

NHSX is working with the market at a national level to create a platform of digital tools like NHS Login that can be built on by digital health innovators.

In September 2019, the National Institute for Health and Care Excellence (NICE) published three new interventional procedure guidance (for implant insertion for prominent ears, high-intensity focused ultrasound for glaucoma, and bioprosthetic plug insertion for anal fistula) and five new MedTech innovation briefings (for SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea, The V.A.C. Veraflo Therapy system for infected wounds, UroShield for preventing catheter-associated urinary tract infections, InterDry for intertrigo, and Alpha-Stim AID for anxiety).

In August 2019, the National Institute for Health and Care Excellence published one new MedTech innovation briefings for vacuum therapy for colorectal anastomotic leakage and two new interventional procedure guidance for endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms and the Papillon technique for locally advanced rectal cancer.

In May and November each year, NHS England makes decisions on which new treatments should be included for routine commissioning. The decisions are taken by the NHS England Board based on recommendations from the Clinical Priorities Advisory Group (CPAG), which is made up of doctors, health experts, and patient representatives.

NICE issued a consultation document about safety and efficacy of balloon cryoablation for Barrett’s oesophagus and squamous dysplasia of the oesophagus and balloon dilation for eustachian tube dysfunction which were considered for Interventional Procedures Guidance in development for public consultation until 20 September 2019.

The Clinical Coding and Schedule Development (CCSD) group develop and maintains procedural and diagnostics nomenclature for private payers in England. New procedure codes concern hip replacement, endoscopic ablation, multiple arthroscopic operations on the ankle, collagen paste for closing an anal fistula and diagnostic codes for tests for next generations sequencing molecular intelligence, and others. The codes are introduced with a recommended adoption date being the 1st of November 2019. The documents also contain a list of textual changes in codes, inactivated codes, and an updated list of unacceptable combinations of codes.

In July 2019, the National Institute for Health and Care Excellence (NICE) published one new diagnostics guidance for therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis, two new interventional procedure guidance (for transurethral laser ablation for recurrent non-muscle-invasive bladder cancer and ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids), and one new MedTech innovation briefing for HemaClear for bloodless surgical field during limb surgery.

The overview includes key stakeholders, money flow, the structure of the NHS Scotland, payment model in the system, the role of the Scottish National Tariff, Specialised Clinical Services, commissioning of services outside Scotland (in England and EU), the role of health technology assessment.

NHSX has officially launched in July 2019 bringing together teams from the Department of Health and Social Care and NHS England and NHS Improvement, to lead the largest digital health and social care transformation program in the world. With an investment of more than £1 billion pounds a year nationally and a significant additional spend locally, NHSX has been created to give staff and citizens the technology they need.

The Clinical Coding and Schedule Development (CCSD) group develop and maintains procedural and diagnostics nomenclature for private payers in England. New procedure codes concern mastectomy and immediate reconstruction of the breast, coronary intravascular lithotripsy, angioplasty, insertion of a stent, portal vein embolization, and others and diagnostic codes for tests for primary hyperoxaluria panel, myeloid panel, and hereditary angioedema. The codes are introduced with a recommended adoption date being the 1st of August 2019. The documents also contain a list of textual changes in codes and an updated list of unacceptable combinations of codes.